Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Time to Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw unusually-strong trading volume on Thursday . Approximately 4,206 shares traded hands during mid-day trading, an increase of 19% from the previous session’s volume of 3,538 shares.The stock last traded at $10.10 and had previously closed at $10.01.

Bavarian Nordic Stock Performance

The business has a fifty day simple moving average of $9.90 and a 200 day simple moving average of $9.98. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 13.38 and a beta of 1.21.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.The firm had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.